Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SciClone Enters $84 Million China Deal for Novel Conjugate Aimed at Solid Tumors

publication date: Mar 20, 2020

SciClone Pharma signed an $84 million deal to acquire Greater China rights to a novel drug conjugate aimed at solid tumors from Tarveda Therapeutics of Massachusetts. PEN-866, the initial clinical program in Tarveda’s HSP90 binding miniature drug conjugate platform, is designed to bind to the activated form of Heat Shock Protein 90 (HSP90) to accumulate and release its topoisomerase 1 inhibitor payload in solid tumors. SciClone will make a $4 million upfront payment, be responsible for up to $75 million in milestones, and can make a $5 million investment in Tarveda. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital